Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B
Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE: TMO) ("Thermo Fisher") for $4.
As tariffs loom, 3M-spinoff Solventum’s operating margins are continuing to shrink while its investors look toward the ...
M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its wound care and surgical sterilization products.
Nelson Peltz’s firm has held a roughly 5% stake in Solventum since the middle of last year. Solventum, which sells healthcare ...
Reports Q4 revenue $2.074B, consensus $2.05B. “Solventum (SOLV) executed another quarter of solid performance, enabling us to deliver full year ...
Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...
The Maplewood, Minnesota-based company said it had net income of 17 cents per share. Earnings, adjusted for one-time gains and costs, were $1.41 per share. The results topped Wall Street expectations.
Solventum Logo (PRNewsfoto/3M Healthcare US Opco LLC) "Solventum executed another quarter of solid performance, enabling us to deliver full year 2024 at the high end of our expect ...
Trian Fund Management, which beneficially owns about 5% of Solventum (SOLV) and is the company’s largest active shareholder, commented on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback